A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
D. Rizzieri
No relevant relationships to disclose
U. Krug
No relevant relationships to disclose
R. F. Schlenk
No relevant relationships to disclose
N. Vey
No relevant relationships to disclose
X. G. Thomas
No relevant relationships to disclose
F. Huguet
No relevant relationships to disclose
M. Johansen
Employment or Leadership Position - Clavis Pharma
Honoraria - Clavis Pharma
Research Funding - Clavis Pharma
T. F. Jacobsen
Employment or Leadership Position - Clavis Pharma
Stock Ownership - Clavis Pharma
Honoraria - Clavis Pharma
Research Funding - Clavis Pharma